• Most Popular
  • Most Shared

Pharmacyclics cancer drug not approvable--US FDA

Fri Dec 21, 2007 7:17pm EST

Stocks

   

LOS ANGELES, Dec 21 (Reuters) - Drug developer Pharmacyclics Inc (PCYC.O) said on Friday that the U.S. Food and Drug Administration turned down its application to market Xcytrin as a treatment for non-small cell lung cancer which has spread to the brain.

The company said in a statement that it continues to believe that Xcytrin is a novel active cancer drug and will seek a corporate partner to help support future development.

Pharmacyclics said it expects data in the first half of 2008 from three Phase 2 trials evaluating the drug in patients with advanced relapsed non-small cell lung cancer.

The company had been seeking approval for use of Xcytrin in combination with whole brain radiation therapy. (Reporting by Deena Beasley in Los Angeles; Editing by Gary Hill)



More from Reuters

Photo

Accused 9/11 plotters may face NY "Guantanamo"

NEW YORK (Reuters) - If the men accused of plotting the September 11 attacks wonder what conditions they might face when they are moved to New York from Guantanamo Bay for trial, they can expect solitary confinement, 23-hour-a-day lockdowns, constant video surveillance and almost no visitors.

» More Top News
Traders in the oil options pit work at the New York Mercantile Exchange, September 9, 2008. REUTERS/Chip East
Analysis:

"More assumptions, more risk"

New oil and gas reserve rules were supposed to improve transparency, but the unforeseen consequences of the regulations could add a layer of uncertainty for investors.  Full Article 

regulatory news
The sun sets over the Mackenzie Delta near Inuvik, Northwest Territories November 11, 2009. Credit: REUTERS/Jeffrey Jones

An Arctic economy in limbo

Beset by political and economic setbacks, one of the world's biggest pipeline projects is on hold, and it's unclear if the project will ever break ground.  Full Article 

Green Business